Endocrine Abstracts

Objectives: Currently 131I treatment after surgery is suggested in selected intermediate-risk and in high-risk patients with DTC. In patients with radio-avid structural disease and in those with biochemical disease a second 131I treatment could be considered. However data about the impact of the second 131I treatment on clinical status remains controversial.Methods: Clinical data of 231 DTC patients followed at the Unit o...

GEP NETs, especially gastrinomas, occur in 40–70% of MEN1 patients and represent the main cause of death in these patients.We aim to investigate the efficacy of lanreotide autogel (ATG) in the treatment of MEN1-related gastrinomas.We report a monocentric series of seven MEN1 patients (three M, and four F) treated with lanreotide ATG (120 mg/4 weeks) for a mean period of 62.1 months. Plasma gastrin levels have been measured at ...

Context: Thyrotoxicosis is the most common endocrine adverse event due totreatment with anti-PD1 and anti-PD-L1. The most common form is destructive thyrotoxicosis whereas persistent, supposedly autoimmune hyperthyroidism (Graves’ hyperthyroidism) is rare. The possible role of thyroid imaging (neck ultrasound and scintigraphy) in the differential diagnosis has never evaluated.Aim: To evaluate the usefulness of neck ultrasound and 99Tc- s...